tiprankstipranks
Immatics Sees Revenue Surge Despite R&D Expenses
Company Announcements

Immatics Sees Revenue Surge Despite R&D Expenses

Immatics (IMTX) has released an update.

Pick the best stocks and maximize your portfolio:

Immatics reported a significant increase in collaboration revenue for the nine months ending September 30, 2024, reaching €99.6 million compared to €38.1 million in the same period last year. Despite higher revenue, the company faced substantial research and development expenses, which contributed to a loss before taxes of €2.4 million for Q3 2024. Investors should note the company’s ongoing focus on R&D, which may impact financial performance in the near term.

For further insights into IMTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskImmatics Faces Termination of Key Collaboration with Bristol Myers Squibb
TipRanks Auto-Generated NewsdeskImmatics N.V. Reports Strong Q3 2024 Progress and Financials
TheFlyImmatics moved to Buy from Not Rated at Goldman Sachs
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App